📰 Hartmutj Ehrlich News
Page 3 - Hartmutj Ehrlich News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hartmutj Ehrlich. Real-time updates on events, politics, business and more.
April 5, 2023
Marc's appointment bolsters Abivax's position as a leader in the field of chronic inflammatory bowel diseasesCorinna zur Bonsen-Thomas steps down as acting Chair and remains a Board MemberProf. Hartmut
February 22, 2023
EQS-News: ABIVAX / Key word(s): Capital IncreaseAbivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors 22.02.2023 / 18:05 CET/CESTThe issuer is solely responsible for the content of this announcement.NOT FOR DISTRIBUTION IN OR INTO THE...
February 22, 2023
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONSAbivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US
February 17, 2023
EQS-News: ABIVAX / Key word(s): PersonnelAbivax appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer 17.02.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax appoints Dr. Sheldon Sloan, M.D., as Chief Medical OfficerSheldon Sloan, M.D., M. Bioethics, has a strong...
February 17, 2023
Sheldon Sloan, M.D., M. Bioethics, has a strong track record in product development and commercial launches in the pharmaceutical industry with a focus on Inflammatory Bowel DiseaseAs CMO of Abivax, Dr.
February 14, 2023
Abivax will be presenting a poster on blood and rectal tissue data from ulcerative colitis (UC) patients, confirming the novel mechanism of action of obefazimod based on the upregulation of a single microRNA
February 14, 2023
EQS-News: ABIVAX / Key word(s): ConferenceAbivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO 14.02.2023 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax to present blood and rectal tissue data from UC patien...
January 31, 2023
A review study has published the mechanisms and benefits of Abivax's ABX464 to treat inflammatory diseases, including ulcerative colitis.
January 31, 2023
ABX464 continues to be effective over time at keeping patients with moderate-to-severe ulcerative colitis in clinical remission, data show.
January 31, 2023
Abivax completed patient enrollment ahead of schedule for a trial testing ABX464 for people with moderate to severe ulcerative colitis.